Drug intelligence / Profile preview

64Cu-DOTA-U3-1287

Development stage: Unknown
Lead developer: Washington University School of Medicine
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

64Cu-DOTA-U3-1287 is a radiolabeled monoclonal antibody developed for PET imaging. It consists of patritumab (U3-1287, AMG 888), a fully human anti-HER3 monoclonal antibody, conjugated with DOTA and labeled with the radioisotope copper-64. The antibody component binds to and blocks the activation of HER3 (Human Epidermal Growth Factor Receptor 3), while the radioactive copper-64 allows for PET imaging to assess receptor occupancy and tumor uptake. It was initially developed by Washington University School of Medicine for use in patients with advanced solid tumors where HER3 expression is expected.

Other names: 64Cu-DOTA-patritumab

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on 64Cu-DOTA-U3-1287.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 64Cu-DOTA-U3-1287.

Explore the full profile